Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)

COVID-19 Clinical Trial

Official title:

Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04582344
• Other study ID #: 9026-ASI
• Status: Completed
• Phase: Phase 3
• Start date: September 14, 2020
• Est. completion date: July 27, 2022

Study information

• Verified date: August 2022
• Source: Health Institutes of Turkey
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.

Description:

This study is a randomized, double-blinded, multi-center, placebo-controlled phase III clinical trial in adults aged 18~59 years. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental SARS-CoV-2 inactivated vaccine. The experimental vaccine and placebo were both manufactured by Sinovac Research & Development Co., Ltd. A total of 13.000 subjects will be enrolled. Participant will be assigned to receive two doses of experimental vaccine or placebo on the schedule of day 0,14. It is planned that the study will be conducted with two separate cohorts. The first cohort will be healthcare workers in the high risk group (K-1) and the second cohort will be people at normal risk (K-2). After 2 doses of vaccination of 1300 volunteers are completed, safety data will be evaluated by the data safety monitoring board without breaking the blinding, and if there is no safety issue, the K2 cohort will continue to be vaccinated.1.300 volunteers, including 650 volunteers SARS-CoV-2 vaccine and placebo arms, will be included in the K-1 cohort. In the K-2 cohort (normal risk group for COVID-19), 7.650 volunteers were planned to be included in the SARS-CoV-2 vaccine group, and 3.500 volunteers in the placebo group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10214
• Est. completion date: July 27, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• 18-59 years of age (including 18 and 59 years of ages),

• For only K1 cohort, health care workers such as medical doctor, nurse, ward boy, cleaner, hospital technician, administrative personnel who work in any department of a hospital.

• Signed informed consent

Exclusion Criteria:

• Previously PCR positive for COVID-19

• IgG or IgM is positive

• For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination

• Known allergy to components of the study vaccine or control

• Use of immunosuppressant therapy regimens within the six months prior to enrollment in the study or planned use within the two years following enrollment. Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others

• Use of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Immunosuppressive doses of corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for longer than one week. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant

• History of asplenia

• History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture

• Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional or family problems, indicated by clinical history

• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

• Participation in another clinical trial with an investigational product in the six months prior to enrollment in the study or planned participation in another clinical trial within the two years following enrollment

• Received live attenuated virus vaccine 14 days prior to enrollment in the study

• Inactivated vaccine or sub unit vaccine 7 days prior to enrollment in the study

• Fever (oral temperature >37.2?, axillary temperature will not be accepted) within the past 24 hours

• Any other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety/rights of potential participants at risk or prevent them from complying with this protocol.

• Any confirmed or suspected autoimmune disease or immunodeficiency disease, including human immunodeficiency virus (HIV) infection.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• CoronaVac
Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
• Placebo
Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.

Locations

Country	Name	City	State
Turkey	Çukurova University Faculty of Medicine, Department of Infectious Diseases	Adana
Turkey	Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Ankara	Turkey Region
Turkey	Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology	Ankara
Turkey	T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital	Ankara
Turkey	T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic	Ankara	Turkey Region
Turkey	T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases	Ankara	Turkey Region
Turkey	Akdeniz University Faculty of Medicine, Department of Infectious Diseases	Antalya
Turkey	Bursa Uludag University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Bursa
Turkey	Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Diyarbakir
Turkey	Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Gaziantep
Turkey	Acibadem Atakent Hospital, Infectious Diseases and Clinical Microbiology	Istanbul
Turkey	Cerrahpasa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology	Istanbul
Turkey	Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine	Istanbul
Turkey	Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Istanbul
Turkey	T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital	Istanbul
Turkey	T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Tasçioglu City Hospital, Infectious Diseases Clinic	Istanbul
Turkey	T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital	Istanbul
Turkey	University of Health Sciences Istanbul Ümraniye Training and Research Hospital	Istanbul
Turkey	Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases	Izmir
Turkey	Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital	Izmir
Turkey	T.R. Ministry of Health Izmir Provincial Health Directorate Izmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases	Izmir
Turkey	T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department	Kayseri
Turkey	Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology	Kocaeli
Turkey	Malatya Inönü University Faculty of Medicine, Department of Infectious Diseases	Malatya
Turkey	Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology	Trabzon

Sponsors (1)

Lead Sponsor	Collaborator
Health Institutes of Turkey

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19	The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19	2 weeks after the second dose of vaccination
Secondary	Protection Indexes of One Vaccine Dose For Symptomatic COVID-19	The protection rate of, at least, one dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19 Two weeks after the last dose vaccination.	2 weeks after the second dose of vaccination
Secondary	Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death	The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against rates of hospitalization, disease severity/and death two weeks after the second dose of vaccination	2 weeks after the second dose of vaccination
Secondary	Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection	The protection rate of a two dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed SARS-CoV-2 infection two weeks after the second dose of vaccination	2 weeks after the second dose of vaccination
Secondary	Safety indexes of adverse reactions in 28 days	The incidence of adverse reactions from the day of first vaccination to 28 days after the second dose of vaccination.	28 days after the second dose of vaccination
Secondary	Safety indexes of adverse reactions in 7 days	The incidence of adverse reactions within 7 days after each dose of vaccination	7 days after each dose of vaccination
Secondary	Safety indexes of serious adverse events in 1 year	The incidence of SAEs from the first vaccination to one year after the second dose vaccination	1 year after second dose of vaccination
Secondary	Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days	The seroconversion rate, seropositivity rate 14 days after each dose vaccination	14 days after each dose vaccination
Secondary	Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days	The seroconversion rate, seropositive rate 28 days after the second dose vaccination	28 days after the second dose vaccination
Secondary	Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days	GMT and GMI of neutralizing antibody and IgG 14 days after each dose vaccination	14 days after each dose vaccination
Secondary	Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days	GMT and GMI of neutralizing antibody and IgG 28 days after the second dose vaccination	28 days after the second dose vaccination